Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
暂无分享,去创建一个
Robert Gray | R. Gray | J. Schiller | A. Dowlati | A. Sandler | J. Brahmer | R. Lilenbaum | M. Perry | Alan Sandler | David H Johnson | Afshin Dowlati | Michael C Perry | Julie Brahmer | Joan H Schiller | Rogerio Lilenbaum | David H. Johnson
[1] Ricky T. Tong,et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.
[2] Anthony J. Guidi,et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. , 1995, Human pathology.
[3] M. Volm,et al. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. , 1996, British Journal of Cancer.
[4] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[5] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[6] E. Perez,et al. A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100 , 2006 .
[7] N. Ferrara. VEGF and its receptors , 2004 .
[8] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[9] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[10] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[11] R. Robles,et al. Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S , 2005 .
[12] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[13] M. Christian,et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. , 1999, Journal of the National Cancer Institute.
[14] Napoleone Ferrara,et al. The role of vascular endothelial growth factor in pathological angiogenesis , 2004, Breast Cancer Research and Treatment.
[15] A. Jubb,et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[17] E. Manseau,et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. , 1993, Cancer research.
[18] David M Jablons,et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Catalano,et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 , 2005 .
[20] Christopher Jennison,et al. Interim analyses: the repeated confidence interval approach , 1989 .
[21] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[22] K. Hillan,et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. , 1999, Anticancer research.
[23] K. Uematsu,et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. , 2006, Lung cancer.
[24] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .